Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan

Gynecologic Oncology

Volumn 100, Issue 2, 2006, Pages 365-371

  Amikura, Takayuki ^a   Sekine, Masayuki ^a   Hirai, Yasuo ^b   Fujimoto, Seiichiro ^c   Hatae, Masayuki ^d   Kobayashi, Iwao ^e   Fujii, Tsuneo ^f   Nagata, Ichiro ^g   Ushijima, Kimio ^h   Obata, Koshiro ⁱ   Suzuki, Mitsuaki ^j   Yoshinaga, Mitsuhiro ^k   Umesaki, Naohiko ^l   Satoh, Shinji ^m   Enomoto, Takayuki ⁿ   Motoyama, Satoru ^o   Nishino, Koji ^a   Haino, Kazufumi ^a   Tanaka, Kenichi ^a   Arakawa, Atsushi ^p   Ishimaru, Tadayuki ^q   Izuma, Shinji ^r   Ichikawa, Hisashi ^s   Ito, Yuji ^t   Inoue, Tohru ^u   Iwamoto, Mari ^v   Osada, Hisao ^w   Oshima, Kazuya ^x   Oda, Takaaki ^y   Ohno, Masayuki ^z   Katabuchi, Hidetaka ^aa   Kanazawa, Koji ^ab   Kamata, Hiroyuki ^ac   Kitai, Hirokatsu ^ad   Kidera, Yoshiro ^ae   Kudo, Takafumi ^af   Kuzuya, Kazuo ^ag   Kobayashi, Hiroshi ^ah   Sakamoto, Hideki ^ai   Sasaki, Shigeru ^aj   Saji, Fumitaka ^ak   Jimbo, Tsuneo ^al   Jobo, Toshiko ^am   Suzuki, Akira ^an   Suzuki, Kenji ^ao   Sudo, Masato ^ap   Takahashi, Michiko ^aq   Takizawa, Ken ^ar   Tazaki, Tamikazu ^as   Tajima, Hideo ^at   Tanaka, Tadao ^au   Taniguchi, Ichiro ^av   Tamaya, Teruhiko ^aw   Tsujimoto, Masahiko ^ax   Tsunawaki, Akitsu ^ay   Teramoto, Yoshihiro ^az   Toyoda, Nagayasu ^ba   Nogami, Yasuji ^bb   Noda, Tsuneo ^bc   Hasegawa, Kazuo ^bd   Hirakawa, Toshio ^be   Fujii, Hideharu ^bf   Fujiwara, Keiichi ^bg   Mandai, Masaki ^bh   Mori, Toshihisa ^bi   Yajima, Masazumi ^bj   Yasuda, Makoto ^bk   Yamato, Tatsuo ^bl   Yamamoto, Kumio ^bm   Yamamoto, Tsutomu ^bn   Yamamoto, Yasuhisa ^bo   Wada, Yuichi ^bp   more..

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Cancer Institute Hospital   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d Kagoshima City Hospital   (Japan)

^e NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^f National Hospital Organization   (Japan)

^g NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^h KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j JICHI MEDICAL UNIVERSITY   (Japan)

^k KAGOSHIMA UNIVERSITY   (Japan)

^l School of Medicine   (Japan)

^m TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ OSAKA UNIVERSITY   (Japan)

^o KOBE UNIVERSITY   (Japan)

^p NAGOYA CITY UNIVERSITY   (Japan)

^q NAGASAKI UNIVERSITY   (Japan)

^r OSAKA MEDICAL COLLEGE   (Japan)

^s Sekishindo Hospital   (Japan)

^t ST MARY S HOSPITAL   (United States)

^u TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^v EHIME UNIVERSITY   (Japan)

^w CHIBA UNIVERSITY   (Japan)

^x NANTAN GENERAL HOSPITAL   (Japan)

^y Nat Kokura Hosp   (Japan)

^z KAGAWA UNIVERSITY   (Japan)

^aa KUMAMOTO UNIVERSITY   (Japan)

^ab UNIVERSITY OF THE RYUKYUS   (Japan)

^ac TOCHIGI CANCER CENTER   (Japan)

^ad SAITAMA SOCIAL INSURANCE HOSPITAL   (Japan)

^ae Sasebo Kyosai Hospital   (Japan)

^af OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^ag AICHI CANCER CENTER HOSPITAL   (Japan)

^ah HAMAMATSU UNIVERSITY   (Japan)

^ai NIHON UNIVERSITY   (Japan)

^aj NIPPON MEDICAL SCHOOL   (Japan)

^ak OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^al TOKYO ROSAI HOSPITAL   (Japan)

^am KITASATO UNIVERSITY   (Japan)

^an OSAKA NATIONAL HOSPITAL   (Japan)

^ao Keiyu Hospital   (Japan)

^ap Yamamoto General Hospital   (Japan)

^aq Seitama Cancer Center

^ar MITSUI MEMORIAL HOSPITAL   (Japan)

^as Social Insurance Kurume Daiichi Hospital   (Japan)

^at SAITAMA MEDICAL UNIVERSITY   (Japan)

^au JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^av OITA PREFECTURAL HOSPITAL   (Japan)

^aw GIFU UNIVERSITY   (Japan)

^ax OSAKA POLICE HOSPITAL   (Japan)

^ay CITY GENERAL HOSPITAL   (United Kingdom)

^az National Hospital Organization   (Japan)

^ba MIE UNIVERSITY   (Japan)

^bb Gunma Social Insurance Hospital   (Japan)

^bc SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^bd HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^be KYUSHU UNIVERSITY   (Japan)

^bf NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^bg KAWASAKI MEDICAL SCHOOL   (Japan)

^bh KYOTO UNIVERSITY   (Japan)

^bi Kitakyusyu City Medical Center   (Japan)

^bj TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^bk JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^bl Kosei General Hospital   (Japan)

^bm Osaka City Gen Med Treatm Center   (Japan)

^bn Koshigaya Municipal Hospital   (Japan)

^bo Omoto Hospital

^bp SENDAI CITY MEDICAL CENTER   (Japan)

more..

Author keywords

BRCA1; Ovarian cancer; p21; p53

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CELL CYCLE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; JAPAN; MUCINOUS CARCINOMA; MUTATIONAL ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; SOMATIC MUTATION;

ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENES, BRCA1; GENES, P53; GERM-LINE MUTATION; HUMANS; JAPAN; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS;

EID: 30444441412     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.09.010     Document Type: Article

References (30)

1. J. Boyd Molecular genetics of hereditary ovarian cancer Oncology (Huntingt) 12 1998 399 406
2. H. Sobol, D. Stoppa-Lyonnet, B. Bressac-de Paillerets, J.P. Peyrat, J.-M. Guinebretiere, and J. Jacquemier BRCA1-p53 relationship in hereditary breast cancer Int. J. Oncol. 10 1997 349 353
3. E. Rhei, F. Bogomolniy, M.G. Federici, D.L. Maresco, K. Offit, and M.E. Robson Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers Cancer Res. 58 1998 3193 3196
4. D. Bertwistle, and A. Ashworth Functions of the BRCA1 and BRCA2 genes Curr. Opin. Genet. Dev. 8 1998 14 20
5. C. Bernstein, H. Bernstein, C.M. Payne, and H. Garewal DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis Mutat. Res. 511 2002 145 178
6. T. Crook, L.A. Brooks, S. Crossland, P. Osin, K.T. Barker, and J. Waller p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours Oncogene 17 1998 1681 1689
7. K.A. Phillips, K. Nichol, H. Ozcelik, J. Knight, S.J. Done, and P.J. Goodwin Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations J. Natl. Cancer Inst. 91 1999 469 473
8. S.L. Rose, and R.E. Buller The role of p53 mutation in BRCA1-associated ovarian cancer Minerva Gynecol. 54 2002 201 209
9. M.L. Agarwal, W.R. Taylor, M.V. Chernov, O.B. Chernova, and G.R. Stark The p53 network J. Biol. Chem. 273 1998 1 4
10. P.T. Ramirez, D.M. Gershenson, G. Tortolero-Luna, L.M. Ramondetta, D. Fightmaster, and J.T. Wharton Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16INK4a, p21WAF1/Cip-1, and p53 Gynecol. Oncol. 83 2001 543 548
11. A.A. Elbendary, F.D. Cirisano, A.C. Evans, P.L. Davis, J.D. Iglehart, and J.R. Marks Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells Clin. Cancer Res. 2 1996 1571 1575
12. M. Sekine, H. Nagata, S. Tsuji, Y. Hirai, S. Fujimoto, and M. Hatae The Japanese Familial Ovarian Cancer Study Group: mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population Clin. Cancer Res. 7 2001 3144 3150
13. D. Tong, M. Stimpfl, A. Reinthaller, N. Vavra, S. Mullauer-Ertl, and S. Leodolter BRCA1 gene mutations in sporadic ovarian carcinomas: detection by PCR and reverse allele-specific oligonucleotide hybridization Clin. Chem. 45 1999 976 981
14. A. Douglas, M.D. Levine, G. Mark, M.S. Federici, E. Victor, and M.D. Reuter Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer Gynecol. Oncol. 85 2002 431 434
15. J.O. Schorge, M.G. Muto, S.J. Lee, L.W. Huang, W.R. Welch, and D.A. Bell BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis Cancer Res. 60 2000 1361 1364
16. R.E. Buller, T.A. Lallas, M.S. Shahin, A.K. Sood, M. Hatterman-Zogg, and B. Anderson The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer Clin. Cancer Res. 2001 7 2001 831 838
17. S.J. Ramus, L.G. Bobrow, P.D. Pharoah, D.S. Finnigan, A. Fishman, and M. Altaras Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours Genes Chromosomes Cancer 25 1999 91 96
18. J.L. Hilton, J.P. Geisler, J.A. Rathe, M.A. Hattermann-Zogg, B. DeYoung, and R.E. Buller Inactivation of BRCA1 and BRCA2 in ovarian cancer J. Natl. Cancer Inst. 94 2002 1396 1406
19. M.M. Quezado, C.A. Moskaluk, B. Bryant, S.E. Mills, and M.J. Merino Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma Hum. Pathol. 30 1999 203 207
20. R. Hakem, J.L. de la Pompa, A. Elia, J. Potter, and T.W. Mak Partial rescue of BRCA1 (5-6) early embryonic lethality by p53 or p21 null mutation Nat. Genet. 16 1997 298 302
21. R. Hakem, J.L. de la Pompa, C. Sirard, R. Mo, M. Woo, and A. Hakem The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse Cell 85 1996 1009 1023
22. K. Somasundaram Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair-perhaps through transcription J. Cell. Biochem. 88 2003 1084 1091
23. L.A. Terry, J. Boyd, D. Alcorta, T. Lyon, G. Solomon, and G. Hannon Mutation analysis of the p21?WAF1/CIP1/SDI1 cording region in human tumor cell lines Mol. Carcinog. 16 1996 221 228
24. R. Konishi, S. Sakatani, K. Kiyokane, and K. Suzuki Polymorphisms of p21 cyclin-dependent kinase inhibitor and malignant skin tumors J. Dermatol. Sci. 24 2000 177 183
25. L.A. Martinez, J. Yang, E.S. Vazquez, C. Rodriguez-Vargas Mdel, M. Olive, and J.T. Hsieh p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells Carcinogenesis 23 2002 1289 1296
26. M. Pieretti, C. Hopenhayn-Rich, N.H. Khattar, Y. Cao, B. Huang, and T.C. Tucker Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival Cancer Invest. 20 2002 11 23
27. N. Sato, H. Tsunoda, M. Nishida, Y. Morishita, Y. Takimoto, and T. Kubo Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary Cancer Res. 60 2000 7052 7056
28. Y. Cho, S. Gorina, P.D. Jeffrey, and N.P. Pavletich Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations Science 265 1994 346 355
29. M. Harvey, H. Vogel, D. Morris, A. Bradley, A. Bernstein, and L.A. Donehower A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice Nat. Genet. 9 1995 305 311
30. G. Liu, T.J. McDonnell, R. Montes de Oca Luna, M. Kapoor, B. Mims, and A.K. El-Naggar High metastatic potential in mice inheriting a targeted p53 missense mutation Proc. Natl. Acad. Sci. U. S. A. 97 2000 4174 4179